Cell line · CVCL_1329
KLE
Cancer cell line, Homo sapiens. Type II endometrial adenocarcinoma. 45 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. KLE. Cell lines, record CVCL_1329. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1329
On this page
Cell line
As Cellosaurus gives it.
- Name
- KLE
- Accession
- CVCL_1329
- RRID
- RRID:CVCL_1329
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 68Y
- Category
- Cancer cell line
- Diseases
- Type II endometrial adenocarcinoma (NCIt C39749)
- Derived from
- Endometrium (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers45
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Auranofin Potentiates Cisplatin Response in the Setting of Context-Dependent NOTCH-Associated Signaling States in Endometrial Cancer. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer-relevant paralog interplay. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Characterization of CLSP-1025, a First-in-Class, Mutation-Specific T-Cell Engager Targeting a Neoantigen Derived from a Common p53 Mutation. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DHX9 Inhibition Enhances Paclitaxel Sensitivity by Inducing Mitotic Failure in Ovarian and Endometrial Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NSD1-Mediated PPARγ Methylation Enhances PTEN Activity to Suppress Glycolysis and Tumor Progression in Endometrial Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Atopobium vaginae advances endometrial cancer growth via macrophage function in mouse models. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 45
See all 45 papersRelatives2
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | EDITGENE KLE-CopGFP | CVCL_F6C7 | Cell lines | |
| Derived from it | EDITGENE KLE-FLUC | CVCL_F5VH | Cell lines |
Cell banks6
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-1622 | ATCC | |
| BCRJ | 0365 | BCRJ | |
| CCTCC | GDC0115 | Cellosaurus | |
| CLS | 305051 | CLS | |
| EDITGENE | EDC00269 | EDITGENE | |
| IZSLER | BS TCL 230 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1329
GET https://conductscience.org/api/cell-lines/v1/CVCL_1329/papers?page=2